Evaluating cognitive impairment in moyamoya disease patients
Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
Beijing Tiantan Hospital · NCT06832839
This study is trying to see how moyamoya disease affects thinking skills and whether brain surgery can help improve them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 360 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital (other) |
| Locations | 1 site (Beijing, China) |
| Trial ID | NCT06832839 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the risk factors for cognitive decline in patients diagnosed with moyamoya disease. It will utilize advanced techniques such as high-density electroencephalography and multimodal magnetic resonance imaging to identify brain areas affected by cognitive damage. Additionally, the study will explore how cerebral revascularization impacts brain structure and functional networks, and its relationship with cognitive improvement. By understanding these mechanisms, the research seeks to provide insights into the cognitive challenges faced by these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 60 who have been diagnosed with moyamoya disease.
Not a fit: Patients with concurrent cerebrovascular conditions or those outside the age range of 18 to 60 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cognitive impairment in moyamoya disease patients.
How similar studies have performed: While there have been studies on cognitive impairment in cerebrovascular diseases, this specific approach focusing on moyamoya disease is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease. * Please sign the informed consent form. * Participants must be between 18 and 60 years of age. Exclusion Criteria: * Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome. * Individuals younger than 18 years or older than 60 years. * Those with contraindications for magnetic resonance imaging. * Patients who are unable to complete cognitive brain assessments
Where this trial is running
Beijing, China
- Beijing Tiantan Hospital — Beijing, China, China (RECRUITING)
Study contacts
- Study coordinator: Qian Zhang, MD
- Email: zhangqianchina@yahoo.com
- Phone: 8613120012579
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Moyamoya Disease, Cognitive Impairment